# Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

> **NCT06860542** · PHASE2 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 94 (estimated)

## Conditions studied

- Pneumonitis
- Immune-related Adverse Event

## Interventions

- **DRUG:** Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care
- **OTHER:** Arm 1- Usual care

## Key facts

- **NCT ID:** NCT06860542
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860542, "Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06860542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*